Therapy for metastatic melanoma: the past, present, and future

BMC Medicine

Richard W Joseph¹  Svetomir N Markovic²  Laura Finn¹ 

[1]Division of Hematology and Oncology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA

[2]Division of Hematology and Oncology, Mayo Clinic Rochester, Gonda Building 10 South, Rochester, MN 55905, USA

关键词: Therapy;    BRAF;    Ipilimumab;    Vemurafenib;    Melanoma;   

Others  :  1126330
DOI  :  10.1186/1741-7015-10-23

 received in 2011-11-09, accepted in 2012-03-02,  发布年份 2012

【 摘 要 】

Metastatic melanoma is the most aggressive form of skin cancer with a median overall survival of less than one year. Advancements in our understanding of how melanoma evades the immune system as well as the recognition that melanoma is a molecularly heterogeneous disease have led to major improvements in the treatment of patients with metastatic melanoma. In 2011, the US Food and Drug Administration (FDA) approved two novel therapies for advanced melanoma: a BRAF inhibitor, vemurafenib, and an immune stimulatory agent, ipilimumab. The success of these agents has injected excitement and hope into patients and clinicians and, while these therapies have their limitations, they will likely provide excellent building blocks for the next generation of therapies. In this review we will discuss the advantages and limitations of the two new approved agents, current clinical trials designed to overcome these limitations, and future clinical trials that we feel hold the most promise.

【 授权许可】

   
2012 Finn et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA: Cancer Journal for Clinicians 2010, 60:277-300.
• [2]Hill G, Krementz E, Hill H: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. Cancer 1984, 53:1299-1305.
• [3]Atkins M, Lotze M, Dutcher J, Fisher R: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology 1999, 17(7):2105-2116.
• [4]Phan G, Attia P, Steinberg S, White D: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. Journal of Clinical Oncology 2001, 19(15):3477-3482.
• [5]Davies H, Bignell G, Cox C, Stephens P: Mutations of the BRAF gene in human cancer. Nature 2002., 417
• [6]Curtin J, Fridyland J, Kageshita T, Patel H: Distinct sets of genetic alterations in melanoma. New England Journal of Medicine 2005, 353(20):2135-2147.
• [7]Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, Chi Z, Li S, Mao L, Guo J: Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort. European journal of cancer 2011.
• [8]Jakob JA, Bassett RL, Ng CS, Lazar AJF, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Hwu P, Kim KB, et al.: Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. Cancer 2011.
• [9]Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al.: BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Res 2004, 64(19):7099-7109.
• [10]Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, et al.: Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006, 95(5):581-586.
• [11]McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, et al.: Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2008, 26(13):2178-2185.
• [12]Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, et al.: Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma. J Clin Oncol 2009, 27(17):2823-2830.
• [13]Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al.: Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. New England Journal of Medicine 2010, 363(9):809-819.
• [14]Smalley K, Sondak V: Melanoma-an unlikely poster child for personalized cancer therapy. New England Journal of Medicine 2010., 363(9)
• [15]Ribas A, Kim K, Schuchter L, Gonzalez A: BRIM-2: an open label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. Journal of CLinical Oncology, 2011 ASCO Annual Meeting Proceedings 2011, 29(15s):8509.
• [16]Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine 2011, 364(26):2507-2516.
• [17]Kefford R, Arkenau H, Brown M, Millward M: Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Journal of CLinical Oncology, 2010 ASCO Annual Meeting Proceedings 2010, 28(15s):8503.
• [18]Menzies LVAM, Chatfield MSMD, Carlino JR, Howle RA, Scolyer JF, Thompson RF, Kefford GV, Long : BRAF mutation by age-decade and body mass index in metastatic melanoma. Journal of Clinical Oncology 2011., 292011 (suppl; abstr 8507)
• [19]Long KRGV, Carr PJA, et al.: Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (Mut) BRAF kinase: evidence of activity in melanoma brain metastases (Mets). Ann Oncol 2010., 21LBA27 [abstr]
• [20]Dummer JRR, Goldinger SM, Wagner I, Mitchell L, Veronese ML, Nick S, Hilfiker P, Gobbi S: An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J Clin Oncol 2011., 29(suppl; abstr 8548) 2011
• [21]Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, et al.: RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors. New England Journal of Medicine 2012, 366(3):207-215.
• [22]Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L: Immunostimulatory monoclonal antibodies for cancer therapy. Nature reviews Cancer 2007, 7(2):95-106.
• [23]Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al.: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England journal of medicine 2011, 364(26):2517-2526.
• [24]Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine 2010, 363(8):711-723.
• [25]Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, MacConaill LE, Hahn WC, et al.: Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling. Journal of Clinical Oncology 2011, 29(22):3085-3096.
• [26]Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293(5531):876-880.
• [27]Ellis LM, Hicklin DJ: Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clin Cancer Res 2009, 15(24):7471-7478.
• [28]Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al.: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468(7326):973-977.
• [29]Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al.: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468(7326):968-972.
• [30]Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, et al.: Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008, 68(12):4853-4861.
• [31]Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, et al.: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18(6):683-695.
• [32]Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, et al.: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17(1):77-88.
• [33]Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827):1039-1043.
• [34]Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, et al.: Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008, 118(7):2609-2619.
• [35]Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, et al.: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011, 71(7):2750-2760.
• [36]Infante JR, Falchook GS, Lawrence DP, Weber JS: Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 dosed in combination with oral BRAF inhibitor. Journal of CLinical Oncology, 2011 ASCO Annual Meeting Proceedings 2011., 29(18s)
• [37]Jackson GWJ, Hamid O, Schmidt H, Chasalow SD, Alaparthy S, Bao Y, Shahabi V: Assessment of association between BRAF mutation status in melanoma tumors and response to ipilimumab. J Clin Oncol 2011., 292011 (suppl; abstr 2587)
• [38]Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, et al.: Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA 2009, 106(8):2729-2734.
• [39]Fu T, He Q, Sharma P: The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer research 2011, 71(16):5445-5454.
• [40]Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS: A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011, 29(3):489-498.
• [41]Patel SP, Bedikian AY, Papadopoulos NE, Hwu W, Kim KB, Homsi J, Davies MA, Woodman SE, Radvanyi LG, Woodard K, et al.: Ipilimumab plus temozolomide in metastatic melanoma. ASCO Meeting Abstracts 2011, 29(15_suppl):8579.
• [42]Hodi FS, Friedlander PA, Atkins MB, McDermott DF, Lawrence DP, Ibrahim N, Wu X, Zhou J, Giobbie-Hurder A, Murphy G, et al.: A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. ASCO Meeting Abstracts 2011, 29(15_suppl):8511.
• [43]ClinicalTrials.gov [http://www.clinicaltrials.gov] webcite
• [44]Lord J, Hackman R, Moklebust A, Thompson J, Higano C, Chielens D, Steinbach G, McDonald G: Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3⁺ T Cells. Dig Dis Sci 2010, 55(5):1396-1405.
• [45]Curtin JA, Busam K, Pinkel D, Bastian BC: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24(26):4340-4346.
• [46]Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279(5350):577-580.
• [47]Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, Kitamura Y: Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001, 193(4):505-510.
• [48]Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H, Sugahara H, Mitsui H, Kanayama Y, Kitamura Y, et al.: Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995, 85(3):790-798.
• [49]Wakita S, Yamaguchi H, Miyake K, Mitamura Y, Kosaka F, Dan K, Inokuchi K: Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia 2011, 25(9):1423-1432.
• [50]Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, et al.: Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009, 8(8):2079-2085.
• [51]Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F, Azar S, et al.: KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008, 14(21):6821-6828.
• [52]Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, et al.: Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008, 99(5):734-740.
• [53]Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, et al.: Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2011, 29(21):2904-2909.
• [54]Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, et al.: KIT as a therapeutic target in metastatic melanoma. JAMA: the journal of the American Medical Association 2011, 305(22):2327-2334.
• [55]Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M: A phase 2 trial of dasatinib in advanced melanoma. Cancer 2011, 117(10):2202-2208.
• [56]Riese DJ, Gallo RM, Settleman J: Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. Bioessays 2007, 29(6):558-565.
• [57]Frey MR, Edelblum KL, Mullane MT, Liang D, Polk DB: The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF. Gastroenterology 2009, 136(1):217-226.
• [58]Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y: Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009, 41(10):1127-1132.
• [59]Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, Gonzalez FJ, Fabra A: Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 2004, 123(6):1151-1161.
• [60]Srivastava A, Ralhan R, Kaur J: Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications. Microsc Res Tech 2003, 60(2):208-224.
• [61]Perez DG, Suman VJ, Fitch TR, Amatruda T, Morton RF, Jilani SZ, Constantinou CL, Egner JR, Kottschade LA, Markovic SN: Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 2009, 115(1):119-127.
• [62]Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, et al.: BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2012, 30(1):34-41.
• [63]Kottschade LA, Suman VJ, Amatruda T, McWilliams RR, Mattar BI, Nikcevich DA, Behrens R, Fitch TR, Jaslowski AJ, Markovic SN: A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1). Cancer 2011, 117(8):1704-1710.
• [64]Fruehauf JP, Lutzky J, McDermott DF, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim S, et al.: Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, 3, in Patients with Metastatic Melanoma. Clinical cancer research: an official journal of the American Association for Cancer Research 2011.
• [65]Hong DS, Koetz BS, Kurzrock R, Senzer NN, Hanekom W, Naing A, Wheler JJ, Mink J, Ren M, Nemunaitis JJ: Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors. ASCO Meeting Abstracts 2010, 28(15_suppl):2540.
• [66]Keir ME, Butte MJ, Freeman GJ, Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
• [67]Riley JL: PD-1 signaling in primary T cells. Immunol Rev 2009, 229(1):114-125.
• [68]Okazaki T, Honjo T: The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006, 27(4):195-201.
• [69]Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al.: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28(19):3167-3175.
• [70]Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al.: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988, 319(25):1676-1680.
• [71]Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994, 86(15):1159-1166.
• [72]Rosenberg SA, Dudley ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004, 101(Suppl 2):14639-14645.
• [73]Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005, 23(10):2346-2357.
• [74]Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al.: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17(13):4550-4557.
• [75]Dudley ME: Adoptive cell therapy for patients with melanoma. J Cancer 2011, 2:360-362.
• [76]Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, et al.: Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res 2011, 17(14):4882-4891.
• [77]Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(5796):126-129.
• [78]Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, et al.: Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. Journal of Immunotherapy 2012, 35(1):66-72.
• [79]Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM, et al.: Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009, 27(16):2645-2652.
• [80]Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, et al.: gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011, 364(22):2119-2127.
• [81]Joseph RW, Hwu P, Davies MA, Atkins MB, Sullivan RJ: Clinical benefit of ipilimumab in patients with metastatic melanoma who progress on high-dose IL-2. ASCO Meeting Abstracts 2011, 29(15_suppl):8537.
• [82]Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, et al.: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer research 2010, 70(13):5213-5219.
• [83]Allen PJ, Coit DG: The surgical management of metastatic melanoma. Ann Surg Oncol 2002, 9(8):762-770.
• [84]Meyer T, Merkel S, Goehl J, Hohenberger W: Surgical therapy for distant metastases of malignant melanoma. Cancer 2000, 89(9):1983-1991.
• [85]Leo F, Cagini L, Rocmans P, Cappello M, Geel AN, Maggi G, Goldstraw P, Pastorino U: Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 2000, 83(5):569-572.
• [86]Herman P, Machado MA, Montagnini AL, D'Albuquerque LA, Saad WA, Machado MC: Selected patients with metastatic melanoma may benefit from liver resection. World J Surg 2007, 31(1):171-174.
• [87]Rose DM, Essner R, Hughes TM, Tang PC, Bilchik A, Wanek LA, Thompson JF, Morton DL: Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg 2001, 136(8):950-955.
• [88]Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, Liu PY, Unger JM, Flaherty LE, Sondak VK: A phase 2 trial of complete resection for stage IV melanoma: Results of Southwest Oncology Group Clinical Trial S9430. Cancer 2011.